Categories: Health

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation.

  • HemaXellerate is comprised of cells extracted from the patient’s own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body’s ability to generate healthy blood cells.

“Aplastic anemia patients without access to bone marrow transplantation face limited options,” said Dr. David Koos, Chairman and CEO of Regen BioPharma. “With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.”

To ensure the trial’s success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months.

  • Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity.
  • Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market.
  • Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence.

About Regen BioPharma, Inc.

Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION:

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
Email: david.koos@regenbiopharmainc.com or
david.koos@regenbiopharma.com
X (formerly twitter): https://x.com/TheRegenBio 

GlobeNews Wire

Recent Posts

Appeal launched to support people impacted by Newfoundland fires

OTTAWA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the…

2 hours ago

Nokia Corporation – Managers’ transactions (Sahgal)

August 15, 2025 10:00 ET  | Source: Nokia Oyj Nokia CorporationManagers’ transactions15 August 2025 at…

3 hours ago

Nokia Corporation – Managers’ transactions (Fisk)

August 15, 2025 10:00 ET  | Source: Nokia Oyj Nokia CorporationManagers’ transactions15 August 2025 at…

3 hours ago

Saudi Arabia leaps from 104th to 23rd globally in the Mining Investment Attractiveness Index

RIYADH, Saudi Arabia, Aug. 14, 2025 /PRNewswire/ -- Saudi Arabia's mining sector has achieved an unprecedented…

4 hours ago

Startek Philippines wins silver at HR Excellence Awards 2025 for excellence in employee engagement

Recognition highlights the Startek commitment to building an engaged, motivated and high-performing workforce MUMBAI, India, Aug.…

4 hours ago

Celebrate Labor Day Weekend in Las Vegas with Unbeatable Entertainment, Pool Parties and More

LAS VEGAS – This Labor Day weekend, Las Vegas delivers vibrant nightlife, top-tier entertainment and…

5 hours ago